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Abstract
Background: Cowden syndrome (CS) is a cancer predisposition syndrome associated with increased risk of breast,
thyroid, and endometrial cancers, and is characterized by development of benign mucocutaneous lesions.
Case presentation: Here we report on a 58-year-old woman with multiple primary malignancies and subtle
mucocutaneous lesions such as small polyps and wart-like papulas. Over a period of 23 years, she developed various
malignant neoplasms including thyroid, ovarian, stomach, and colon carcinomas, and a benign meningioma. Direct
sequencing analysis of the PTEN gene revealed a novel germline mutation (c.438delT, p.Leu146X).
Conclusion: This case demonstrates that Cowden syndrome is a multi-system disease that can result in the
development of multiple malignant and benign tumors.
Background
Cowden syndrome (CS, OMIM 158350) is an autosomal
dominant disorder characterized by multiple hamarto-
mas, which develop in the skin, thyroid gland, breast,
gastrointestinal tract, and brain [1]. Germline mutations
in the PTEN (phosphatase and tensin homolog deleted
on chromosome ten) gene have been found in 80% of
patients with CS [2]. The PTEN gene encodes a dual-
specificity protein and lipid phosphatase that regulates
the phosphoinositol-3-kinase/Akt signal pathway which
can result in cell cycle arrest in the G1-phase and apop-
tosis [3]. PTEN can directly or indirectly dephosphory-
late focal adhesion kinase (FAK), resulting in inhibition
of cell migration and cell spreading [3-5].
Diagnosing CS remains a challenge due to the varia-
tions in its clinical presentation. A recent molecular-
genetic study estimated that the incidence of CS was
1/200 000, although the actual incidence is likely to be
higher [6]. The pathognomonic features of CS include
mucocutaneous wart-like lesions, which are present in
99% of affected individuals before the age of 30 years
[3]. The other most commonly reported manifestations
are breast carcinomas, thyroid abnormalities, macroce-
phaly, hamartomatous polyps and mental retardation
[7,8]. In women with CS, the lifetime risk of breast can-
cer is estimated to be 25-50%, compared to the general
female population risk of approximately 11%. The life-
time risk of epithelial thyroid cancer can be as high as
10% in both males and females with CS. Follicular carci-
noma is the most common CS-associated thyroid can-
cer, although papillary carcinomas have also been
observed [9,10].
The present report describes the identification of a
novel PTEN germline mutation in a female CS patient
who developed multiple primary tumors and subtle skin
lesions.
Case presentation
A 55-year-old woman suspected to have CS was referred
to the Department of Biology and Medical Genetics,
University Hospital Motol, Prague, for PTEN gene ana-
lysis to confirm the diagnosis.
Her medical history was unremarkable until she devel-
oped a goiter at 34 years of age. At 45 years of age, she
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tion confirmed a macrofollicular adenoma in the left
thyroid lobe and an encapsulated thyroid tumor in
the right thyroid lobe. At 54 years of age she underwent
a total thyroidectomy due to a follicular carcinoma
(Figure 1a).
At 43 years of age she underwent a hysterectomy for
myomatosis and adnexectomy due to an adenopapilo-
carcinoma of the left ovary.
At the age of 49 years, the patient was admitted to
hospital with epileptic paroxysms. A CT scan of the
brain showed a left frontal lesion, which was the cause
of the paroxysms. The lesion was surgically removed
and histopathologically classified as a benign menin-
gioma (Figure 1b). At 53 and 57 years of age, she was
again surgically treated for meningioma recurrence and
a steadily deteriorating condition. Despite those surgical
interventions, there was a progressive decline in cogni-
tive functions and memory.
The initial brain tumor finding together with the
observed cachexia led to the suspicion of metastasis
from an unknown primary cancer. Careful endoscopic
examination revealed hundreds of polyps in the sto-
mach, duodenum and colon. There were numerous
mostly hyperplastic and hamartomatous polyps up to
10 mm in diameter in the stomach. Smaller and multi-
ple sessile polyps were found in the duodenum. The
esophagus was free of any polyps. Along the entire
length of the colon were multiple histopathologically
confirmed hyperplastic and inflammatory polyps as well
as tubulovillous or villous adenomas of 4-10 mm in dia-
meter, with low-grade dysplasia.
At the age of 55 years, the patient was examined by a
clinical geneticist (MS) who observed macrocephaly, a
fissured tongue and a polyp of 0.5 cm in diameter in the
dorsal part of the oral cavity. A few wart-like papules on
the forearms and chest were classified as senile verru-
coid lesions. No other mucocutaneous lesions were
found on the face or oral mucosa. The patient’s mother,
whose medical history was unknown to us, died of
colon cancer at the age of 56 years. No other members
of the family have had signs of CS or any cancer. The
patient had one child who was negatively tested for
mutations in the PTEN gene.
Several biopsies were performed throughout the gas-
trointestinal (GI) tract over a 9-year period, and none
showed evidence of malignant lesions. Then at 57
years of age, histopathological examination of biopsy
material from a hyperplastic polyp in the stomach
revealed a well-differentiated intramucosal adenocarci-
noma of 8 mm in diameter (Figure 1c). One year after
the gastric cancer had been detected, the patient devel-
oped an aggressively growing synchronous adenocarci-
noma of the anorectum (T3N0M0) and the sigmoid
colon (T3N0M0) (Figure 1d). Abdominoperineal sur-
gery (i.e., the Miles’ operation) was performed. How-
ever, the patient died at post-operative 1 month due to
unmanageable complications.
Methods
This study was approved by the Ethics Committee of
the University Hospital Motol, Prague, according to the
Helsinki Principles. After receiving written informed
consent, the genomic DNA of the patient was isolated
from blood leukocytes using a Genomic DNA Purifica-
tion Kit (Gentra Systems, Minneapolis, MI, USA)
according to the manufacturer’sg u i d e .T h eg e n o m i c
DNA was amplified using intronic primers (sequences
are available upon request) flanking the nine exons and
a promoter region of the PTEN gene [11]. The PCR pro-
ducts were purified using a SureClean PCR purification
kit (Bioline, London, UK). Bidirectional cycle sequencing
of the PCR products was performed using a BigDye Ter-
minator v3.1 Cycle Sequencing kit and an ABI 3130
Genetic Analyzer (both from Applied Biosystems, Foster
City, CA, USA).
Results and Discussion
Examination of the genomic DNA revealed a novel het-
erozygous mutation, c.438delT, in exon 5 (Figure 2).
That mutation is predicted to lead to a frameshift that
results in formation of a premature stop codon
(p.Leu146X) for PTEN protein translation. The mutation
is considered to be pathogenic and causative for CS
disease.
Figure 1 Histopathologic examination of the CS patient.
a) Minimally invasive follicular carcinoma of the thyroid gland
(H&E ×100). b) Meningotheliomatous meningioma (H&E ×100). c)
Gastric hyperplastic polyp with adenocarcinoma (H&E ×200). d)
Tubular adenocarcinoma of the large bowel (H&E ×100).
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International Cowden Consortium criteria are found to
harbor a PTEN mutation [12]. Mucocutaneous lesions
are present in 99% of CS patients before the age of
30 years [3]. However, the present patient was not
reported to have had mucocutaneous lesions until 55
years of age, when a targeted examination revealed
subtle skin lesions. The only visible wart-like papules
were found on her forearms. Such lesions are commonly
found in the general population and could therefore
have been overlooked or considered unremarkable.
The most common malignancies associated with CS
are breast and thyroid carcinomas. Benign breast lesions
(fibrocystic breast disease, fibroadenomas) and breast
adenocarcinomas develop in about 76% and 25-50% of
CS-affected females, respectively [3]. The average age of
a breast cancer diagnosis in CS patients is between 38
and 46 years [13]. Marsh et al. observed an association
between the presence of a PTEN mutation and malig-
nant breast disease [12]. In our patient, a mammo-
graphic examination at 57 years of age showed no
evidence of any breast lesions.
Benign thyroid lesions occur in as many as 60% and
thyroid cancers in up to 10% of CS patients [3,9]. Our
patient developed a follicular adenocarcinoma at 54 years
of age, despite regular follow-up and treatment since her
first admission to hospital due to a goiter at 34 years old.
Gynecological abnormalities are reported in 44% of
females with CS [7]. Endometrial cancer is a major diag-
nostic criterion for CS, with an estimated frequency of
5-10% [7]. Ovarian tumors are rare in CS, with only one
report documenting an ovarian dysgerminoma in a CS
patient [14]. The hypothesis that a germline mutation of
the PTEN gene was implicated in the formation of ovar-
ian tumors in CS patients was supported by the identifi-
cation of a somatic loss of heterozygosity (LOH) in the
wild-type allele [14]. The present patient had myomato-
sis of the uterus and adenocarcinoma of the left ovary at
the age of 43 years. Unfortunately, ovary tumor tissue
was not available for LOH analysis.
Macrocephaly and Lhermitte-Duclos disease (dysplastic
cerebellar gangliocytoma) are also major pathognomonic
diagnostic criteria of CS [15]. Meningiomas (benign brain
tumors) have also been described in CS patients, albeit
rarely [16-19]. In our patient, the discovery of a menin-
gioma launched an intensive and thorough follow-up
which revealed additional and continually appearing
symptoms. Benign brain lesions accompanied by epileptic
paroxysms and a steadily deteriorating clinical condition
were her main health problems.
Gastrointestinal polyps (mostly classified as hamartoma-
tous, hyperplastic, inflammatory, juvenile, lymphomatous
and adenomatous) are commonly reported in CS patients,
with frequencies ranging between 35-85% and higher than
90% in Western and Japanese patients, respectively
[9,20-24]. That difference in frequency is considered to
reflect that GI examinations are more common in Japan
[24]. In a study involving 126 CS patients, Marra et al.,
reported that of the 42 patients who underwent a com-
plete GI examination, 36 (85%) had GI polyps. Non-ade-
nomatous polyps that are generally asymptomatic may be
more common in CS patients, especially when GI investi-
gations are not part of the recommended surveillance for
CS. Although an association between CS and GI cancer
remains a topic of debate, reports describing malignant GI
tumors in CS patients have been published [9,21-23,
25-27]. Although non-adenomatous polyps have a weak or
absent malignant potential, there is evidence that carcino-
mas may arise within non-adenomatous polyps [26,28, and
the present study]. Marra et al. stated that adenomatous
polyps represent approximately 25% of CS polyps, and
have a higher malignant potential than non-adenomatous
polyps [22]. During a 9-year follow-up period, the present
patient developed numerous GI polyps with various histo-
pathological features (hyperplastic, inflammatory, hamar-
tomatous and adenomatous). Ultimately, three polyps
(a hyperplastic polyp in the stomach, and adenomatous
polyps in the rectum and the sigmoid colon) progressed to
macroscopic carcinomas.
Conclusion
Although breast and thyroid cancers are the predomi-
nant malignancies in CS patients, it should be empha-
sized that benign and/or malignant tumors may also
develop in the GI tract from pre-existing polyps, and in
the genitourinary tract or in the brain. Most of the stu-
dies that have examined cancer in CS patients do not
Figure 2 DNA sequencing electropherograms. Upper panel:
Electropherogram of the PTEN gene, exon 5, from a healthy control.
Lower panel: Electropherogram of the PTEN gene, exon 5, from the
Cowden syndrome patient. Note the heterozygous deletion
mutation at c.438delT (arrow).
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neoplasm because the patients are relatively young. We
propose that meningiomas and GI tract cancers, albeit
rare, should be a component of the definition of CS.
Physicians who might encounter CS patients should be
aware of the possible neurological and/or GI tract
manifestations.
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